CD8A and neoplasm: Results showed that in addition to hyperactive RAS signaling (Figure S1, Supporting Information), KRAS mutant samples versus KRAS wild‐type counterparts had a significant decrease in CD8+ T‐cell density within tumor tissue, but no discernible difference within the invasive margin (Figure1A,B).